Study of FeNO as a marker for immunotherapy response in lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial is testing whether a simple breath test (FeNO) can predict how well immunotherapy works in people with advanced lung cancer who haven't had treatment before. It's for patients whose tumors have high PD-L1 levels and who will receive immunotherapy alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced non-small cell lung cancer that has spread (metastatic)
- You have not had any previous treatment for your lung cancer
- Your tumor has high PD-L1 levels (more than 50%)
- You are 18 years or older
- You speak and read French
- You can perform a simple breath test (blowing into a device)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study checks whether tiny bits of tumor DNA in the blood can be measured over time in people with non-small cell lung cancer who are receiving immunotherapy. It aims to see if these blood tests can help track the cancer response or changes during treatment.
This study tests a new device that measures a lung marker called FeNO (fractional exhaled nitric oxide) to help diagnose asthma. It may be an option for adults with asthma who have not changed their medication recently and have no recent infections.
This study is testing whether certain white blood cells (called neutrophils) in your tumor can predict how well a combination of chemotherapy and immunotherapy works before surgery for lung cancer. If you qualify, you would receive this treatment and then have surgery, and researchers would track your response.
This study measures a lung inflammation marker called FeNO in ICU patients on a breathing machine. It may help doctors understand lung health and guide treatment.
This trial is testing whether a simple breath test called FeNO can help doctors diagnose asthma more accurately. It's for people who have symptoms that might be asthma, but haven't been diagnosed yet.
This study tests whether a special PET scan can predict how well a first-line combination of chemotherapy and immunotherapy works in people with advanced non-small cell lung cancer. The goal is to see if the scan can help personalize treatment.
Hear when a new Metastatic Non-small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.